USD
+$0.00
(+0.00%
)At Close (As of Sep 18, 2025)
$65.12B
Market Cap
25.29
P/E Ratio
5.81
EPS
$195.13
52 Week High
$138.76
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $6.4B |
Total Revenue | $9.3B |
Cost Of Revenue | $2.9B |
Costof Goods And Services Sold | $2.9B |
Operating Income | $3.4B |
Selling General And Administrative | $2.3B |
Research And Development | $686M |
Operating Expenses | $3B |
Investment Income Net | - |
Net Interest Income | -$119M |
Interest Income | $106M |
Interest Expense | $242M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $497M |
Income Before Tax | $3.1B |
Income Tax Expense | $637M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $2.5B |
Comprehensive Income Net Of Tax | - |
Ebit | $3.4B |
Ebitda | $3.9B |
Net Income | $2.5B |
Field | Value (USD) |
---|---|
Total Assets | $14B |
Total Current Assets | $6B |
Cash And Cash Equivalents At Carrying Value | $2B |
Cash And Short Term Investments | $2B |
Inventory | $2.3B |
Current Net Receivables | $1.3B |
Total Non Current Assets | $8.3B |
Property Plant Equipment | $3.6B |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $1.1B |
Intangible Assets Excluding Goodwill | $1.1B |
Goodwill | $2.7B |
Investments | - |
Long Term Investments | - |
Short Term Investments | $2M |
Other Current Assets | $379M |
Other Non Current Assets | - |
Total Liabilities | $9.5B |
Total Current Liabilities | $3.4B |
Current Accounts Payable | $433M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.4B |
Total Non Current Liabilities | $6.1B |
Capital Lease Obligations | $174M |
Long Term Debt | $5.2B |
Current Long Term Debt | $1.4B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $6.7B |
Other Current Liabilities | $1.5B |
Other Non Current Liabilities | $222M |
Total Shareholder Equity | $4.8B |
Treasury Stock | - |
Retained Earnings | $12B |
Common Stock | $5M |
Common Stock Shares Outstanding | $455M |
Field | Value (USD) |
---|---|
Operating Cashflow | $3B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $497M |
Capital Expenditures | $655M |
Change In Receivables | - |
Change In Inventory | -$40M |
Profit Loss | - |
Cashflow From Investment | -$315M |
Cashflow From Financing | -$2.7B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | $786M |
Dividend Payout Common Stock | $786M |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$1.9B |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $2.5B |
Field | Value (USD) |
---|---|
Gross Profit | $6.4B |
Total Revenue | $9.3B |
Cost Of Revenue | $2.9B |
Costof Goods And Services Sold | $2.9B |
Operating Income | $3.4B |
Selling General And Administrative | $2.3B |
Research And Development | $686M |
Operating Expenses | $3B |
Investment Income Net | - |
Net Interest Income | -$119M |
Interest Income | $106M |
Interest Expense | $242M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $497M |
Income Before Tax | $3.1B |
Income Tax Expense | $637M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $2.5B |
Comprehensive Income Net Of Tax | - |
Ebit | $3.4B |
Ebitda | $3.9B |
Net Income | $2.5B |
Field | Value |
---|---|
Ex Dividend Date | 2025-07-18 |
Declaration Date | 2025-05-21 |
Record Date | 2025-07-18 |
Payment Date | 2025-09-03 |
Amount | 0.5 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Zoetis Inc. (ZTS) is a leading global animal health company dedicated to advancing the health and well-being of livestock and companion animals. As the world's largest producer of medicines and vaccines for pets and livestock, Zoetis leverages innovative research and development to deliver a comprehensive portfolio of products that enhance the productivity of animal farming and improve the health of pets worldwide. With a strong commitment to sustainability and animal welfare, the company positions itself as a vital partner in agriculture and veterinary care, driving growth in a robust market characterized by rising demand for high-quality animal health solutions.